Aquestive Therapeutics Inc (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercialising differentiated products to solve therapeutic problems, announced yesterday that it has named Daniel Barber as its new senior vice president, chief operating officer effective 6 May 2019.
Barber has worked at Aquestive since 2007, most recently in the role of senior vice president, chief strategy and development officer. A twelve-year veteran of Aquestive, Barber held a series of positions of increasing responsibility with the company including finance director, senior director of Alliance Management, and vice president of Business Development. Prior to his tenure at Aquestive, he served in roles at Xerox and Quest Diagnostics.
Keith J Kendall, Aquestive Therapeutics' chief executive officer, said, 'Dan has been a member of the Aquestive team for over a decade and has been integral in helping the Company to evolve into a publicly-traded, specialty pharmaceutical company with a strong developmental pipeline, marketed products, and in-house manufacturing. As our Company continues to grow, Dan's broad skillset will ensure our strategies, capabilities, and operations adapt in line with organizational and market needs.'
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
OncoHost receives BIG Innovation Award in Health category
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees